Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
life sciences
national blog main
biotech
boston
boston top stories
clinical trials
fda
acute hepatic porphyrias
akin akinc
alnylam pharmaceuticals
alprazolam
amgen
aminolevulinic acid
biopharma
cgrp inhibitors
chronic migraine
colucid pharmaceuticals
deals
drug enforcement administration
drugs
duchenne
eli lilly
europe blog main
europe top stories
givosiran
indiana
indiana blog main
indiana top stories
lasmiditan
licensing
m&a
migraine research foundation
muscular dystrophy
national top stories
onpattro
patisiran
paul matteis
raleigh-durham blog main
raleigh-durham top stories
What
approval
3
×
fda
second
3
×
drug
medicine
rna
won
acute
addresses
ago
alnylam
betting
billion
biopharma
causes
condition
deal
decades
duchenne
eli
friday
gene
giant
giving
historic
indicated
interference
lasmiditan
lilly
lilly’s
medication
migraine
new
nod
oks
pharmaceutical
pharmaceuticals
puts
quick
recently
Language
unset
Current search:
second
×
approval
×
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug